[Animal @entity137 studies of XXXX (author's transl)].

@entity1 @entity137 @entity944 @entity19 @entity235 @entity1425 @entity95 @entity2224 @entity5119 @entity35 @entity1370 @entity165
The oral LD50 of @entity5119 in @entity35 and @entity19 was found to be higher than 5 000 mg/kg. Subacute @entity137 studies failed to show any toxic effect in @entity35 and monkeys which received 3 000 and 200 mg/kg/24 h respectively for 90 days. @entity137 studies were carried out in @entity35 during 2 years and in monkeys during 8 years. Daily oral doses of up to 800 mg/kg in @entity35 and 500 mg/kg in monkeys had no demonstrable toxic effects; in particular, there were no differences on electron microscopy between liver sections of monkeys treated for 8 years and those of untreated monkeys. In @entity235 , @entity5119 proved non toxic when given for 14 days. However, during more prolonged administration (90 days) @entity944 occurred in some animals, which was unrelated to dosage or to duration of treatment. Additional studies showed that @entity5119 sensitizes @entity235 myocardium to @entity1425 , thereby inducing @entity2224 . This effect was not observed in other animal species and is considered as specific to @entity235 . A special study was performed in monkeys, which received high doses of @entity5119 (equivalent to 4-15 times the @entity1 dose) associated with an atherogenic diet containing 100 times more @entity165 than their normal diet and large quantities of fats. Some monkeys fainted and died; ECG tracings revealed no other abnormality than an increase in the length of QTc. @entity1370 cannot be extrapolated from animal to @entity1 , since heart monitoring failed to show any abnormality in @entity1 treated with @entity5119 . No mutagenic or carcinogenic effects were observed in @entity35 , and teratological and reproduction studies carried out in @entity35 and @entity95 gave negative results.
